[Effects of liraglutide on the expression of local renin-angiotensin system, transforming growth factor-β1 and collagen type III in pulmonary tissue of diabetic rats].
Zhonghua Yi Xue Za Zhi · 2014
Last updated 2026-05-28In a study of 30 diabetic rats, those given the GLP-1 drug liraglutide for 12 weeks showed lower levels of certain proteins (AT1R, AngII, TGF-β1) and collagen type III in their lung tissue compared to untreated diabetic rats. The treated rats received 400 micrograms of liraglutide per kilogram of body weight daily, and their protein levels were measured using lab tests like RT-qPCR, ELISA, and Western blotting.
AI summary of the abstract below.
| Journal | Zhonghua Yi Xue Za Zhi, 2014 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 0.19 |
| NIH percentile | 13 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
OBJECTIVE: To explore the effects of GLP-1 receptor analog liraglutide on the expression of local renin-angiotensin system (RAS), TGF-β1 and collagen type III in pulmonary tissue of diabetic rats.
METHODS: Thirty male Wistar rats were divided into normal (N), diabetic (DM) and liraglutide treatment (LR) groups according to the table of random number. Diabetes mellitus was induced by feeding with a high-sugar and high-fat diet and a low-dose injection of streptozotocin into caudal vein for 8 weeks. After successful modeling, liraglutide (400 µg×kg(-1)×d(-1)) was administered by a subcutaneous injection for 12 weeks in LR group. At Week 12, the mRNA expression levels of AT1R and TGF-β1 were detected by real-time quantitative polymerase chain reaction (RT-qPCR), the protein expression of AngII was detected by enzyme-linked immunosorbent assay (ELISA) and the protein expression levels of AT1R and transforming growth factor-beta 1 (TGF-β1) were detected by Western blotting (WB). Collagen type III was detected by immunohistochemistry.
RESULTS: The expressions of AT1R,AngII, TGF-β1 and collagen type III increased in DM group than those of N group (P < 0.05). The expressions of AT1R, AngII, TGF-β1 and collagen type III were lower in LR group than those of DM group (RT-qPCR of AT1R: 0.08 ± 0.04 vs 0.32 ± 0.16, WB of AT1R: 1.20 ± 0.11 vs 1.32 ± 0.05; ELISA of AngII: (2.78 ± 0.56) vs (4.04 ± 0.13) ng/L; RT-qPCR of TGF-β1: 0.21 ± 0.11 vs 0.64 ± 0.16, WB of TGF-β1:1.01 ± 0.15 vs 1.19 ± 0.13; mean optical density of Col III:0.11 ± 0.04 vs 0.27 ± 0.04, positive area ratio of Col III:0.056 ± 0.023 vs 0.090 ± 0.026, all P < 0.05).
CONCLUSIONS: Liraglutide plays a role of organ protection by inhibiting the expression of TGF-β1 of pulmonary tissue of diabetic rats. And it may be related with a down-regulation of local RAS.
Verbatim abstract via PubMed 24754994 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.